Adjunct Immunotherapy With Immunoxel in Patients With TB and TB/HIV
This study is enrolling participants by invitation only.
Lisichansk Regional Tuberculosis Dispensary
Information provided by (Responsible Party):
Galyna Kutsyna, Lisichansk Regional Tuberculosis Dispensary
First received: February 2, 2010
Last updated: November 27, 2013
Last verified: November 2013
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is enrolling participants by invitation only.|
|Estimated Study Completion Date:||December 2014|
|Estimated Primary Completion Date:||December 2014 (Final data collection date for primary outcome measure)|
Efremenko YV, Arjanova OV, Prihoda ND, Yurchenko LV, Sokolenko NI, Mospan IV, Pylypchuk VS, Rowe J, Jirathitikal V, Bourinbaiar AS, Kutsyna GA. Clinical validation of sublingual formulations of Immunoxel (Dzherelo) as an adjuvant immunotherapy in treatment of TB patients. Immunotherapy. 2012 Mar;4(3):273-82. doi: 10.2217/imt.11.176.